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Abstract
Background: An a priori combined therapy of a bare metal stent post-dilated with a paclitaxel- 
-coated balloon (PCB) was investigated with optical coherence tomography (OCT) at 2 and  
6 months regarding vessel response. Previous studies have shown inconsistent results and the 
time course of vessel healing after such an interventional strategy is unknown.
Methods: Thirty-three de novo lesions in 32 patients were electively treated. Six-month OCT 
analysis was available in 24 lesions. Two-month OCT follow-up was obtained in 16 lesions. 
Sequential OCT at 2 and 6 months was available in 7 patients. A novel 3-dimensional picture 
of vessel segments as spread outs was implemented.
Results: 6HYHUHLQFRPSOHWHVWHQWDSSRVLWLRQ,6$DFFRPSDQLHGE\VLJQLğFDQWO\ORZHUVWUXW
coverage were found at 2-month compared with 6-month follow-up (ISA struts: 11.4 ± 11.8% 
vs. 1.8 ± 4.8%, p = 0.001; uncovered struts: 14.5 ± 14.8% vs. 2.0 ± 5.3%, p = 0.001). ISA 
size diminished over time and the possibly observed phenomenon of positive vessel remodeling 
(remodeling volume: 4.9 ± 5.9 mm3 at 2-months vs. 2.0 ± 2.6 mm3 at 6-months; p = 0.042) 
was largely reversible in most lesions.
Conclusions: Bare metal stenting with adjunctive application of paclitaxel by a coated bal-
loon shows transient severe incomplete strut apposition, most likely due to focal positive ves-
sel remodeling. Thus, caution is needed in bailout situations following a PCB angioplasty.  
A novel illustration of OCT parameters as “carpet views” enables a comprehensive analysis of 
investigated stents. (Cardiol J 2016; 23, 3: 296–306)
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Introduction
Drug-coated balloons (DCB) haven proven ef-
ğFDF\LQWKHWUHDWPHQWRILQVWHQWUHVWHQRVLVRUDQ-
gioplasty of de novo lesions in small vessels [1, 2]. 
Most DCBs are coated with the mitotic inhibitor 
— paclitaxel. The SeQuent Please™ DCB releases 
!RILWVSDFOLWD[HOORDGE\VLQJOHLQĠDWLRQRI
≥ 30 s [2, 3]. An a priori combination therapy of 
bare metal stent (BMS) implantation post-dilated 
with a paclitaxel-coated balloon (PCB) seems worth 
investigating, since it combines the mechanical 
forces of a stent with an antiproliferative drug ap-
plied in a “single-shot” fashion over a large contact 
surface to the vessel wall [4].
Previous studies have shown inconsistent 
results regarding the antiproliferative strength of 
such an adjunctive procedure [5–10]. Yet, no data 
about the time course of arterial vessel response 
and stent coverage after such a procedure is avail-
able. Optical coherence tomography (OCT) allows 
precise vessel and stent evaluation in vivo. However, 
a three-dimensional (3D) illustration of investigated 
vessel segments that enables simple recognition of 
analyzed OCT parameters at a glance is needed.
We aimed to evaluate vessel response at 2 and 
6 months after an a priori therapy with a BMS 
post-dilated with a PCB regarding incomplete 
stent apposition (ISA) and coverage using OCT. 
A novel 3D analysis of stented vessel segments and 
its comprehensive illustration as spread out charts 
(“carpet-views”) was implemented.
Methods
Study design
%ULHĠ\SDWLHQWVZLWKVWDEOHFRURQDU\DUWHU\
disease and indication for elective percutaneous 
coronary intervention (PCI) of a native coronary 
lesion were included into the OCTOPUS trial. 
Patients were randomly assigned to receive treat-
ment either with the Xience V™ (Abbott Vascular, 
Illinois, USA) drug-eluting stent (DES) or a com-
ELQDWLRQRIWKH%06&RURĠH[%OXHŇSRVWGLODWHG
with the PCB SeQuent Please™ (both BBraun 
Melsungen, Germany) [9, 11]. This sub-study of 
the aforementioned trial focuses only at the treat-
ment arm BMS + PCB at 2- and 6-month OCT 
follow-up (Fig. 1). Due to ethical reasons, only 
patients with an indication for staged PCI received 
serial OCT investigation at both follow-up inter-
vals. The study was conducted at the University 
Hospital of Jena according to the ethical principles 
of the Declaration of Helsinki.
Study devices and interventions
The detailed procedural protocol has been 
published. Only 2.5 mm or 3.0 mm stent diameters 
with two stent lengths (16 mm and 25 mm) were 
allowed. Lesion preparation with pre-dilation or 
direct stenting was conducted on the operator’s 
discretion. To provide a safety margin at the stent 
edges, all BMS were post-dilated with a longer 
PCB (20 mm or 30 mm). Afterwards no further 
intervention of the study lesion was undertaken.
Figure 1. Patient flowchart; BMS — bare metal stent; CAD — coronary artery disease; PCB — paclitaxel-coated balloon; 
PCI — percutaneous coronary intervention; *1 patient received only quantitative coronary angiography at follow-up.
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Angiographic analysis
Quantitative coronary angiography (QCA) 
was performed according to the 15-coronary tree 
segment system (CAAS version 5.9.2, 2012, Pie 
Medical Imaging, Maastricht, Netherlands) by two 
observers (K.N. and S.O.). Late lumen loss was 
GHğQHGDV ĲğQDOPLQLPDO OXPHQGLDPHWHU0/'
post-procedure — MLD at follow-up’, and net lu-
PLQDOJDLQDVĲ0/'DWIROORZXSĽEDVHOLQH0/'ĳ
3URFHGXUDOVXFFHVVZDVGHğQHGDVDUHVLGXDOVWHQR-
VLVGXULQJWKHğQDODQJLRJUDSK\ZLWKRXWDQ\
ĠRZOLPLWLQJGLVVHFWLRQV$QJLRJUDSKLFGLDPHWHU
restenosis of ≥ZDVGHğQHGDVVLJQLğFDQW>@
Optical coherence tomography
Time-domain OCT imaging (M2 CV system, 
LightLab Imaging Inc., Westford, MA, USA) of 
the study stent was performed and images were 
analyzed in 1 mm steps. The detailed OCT protocol 
has been published [9, 11].
OCT parameters
Struts were counted per cross-section and 
classified as either covered or uncovered, and 
regarding apposition as mal-apposed or apposed/ 
/embedded or laying over a side branch ostium. ISA 
ZDVGHğQHGDVDPDODSSRVHGVWHQWVWUXW!ŝP
from the adluminal strut side to the luminal ves-
sel wall. Among others, the following parameters 
were calculated: (1) proliferation volume/cm stent 
length; (2) peak and median relative proliferation 
area = (1 – [minimal lumen area/stent area within 
the same frame]) × 100; (3) remodeling volume 
= integral of (lumen area – stent area + ISA area) 
over stent length; (4) total and relative ISA vol-
umes, and (5) total and relative ISA surface areas. 
Volumetric parameters were computed through the 
integral of area measurements over stent length.
Statistical analysis
Statistical analysis was performed using SPSS 
for Windows (version 21.0.0.0, SPSS, Chicago, Ill). 
Continuous variables are expressed as mean 
± standard deviation and were tested with the one-
way analysis of variance in case of normal distrib-
uted variables. Categorical variables are presented 
as percentages and analyzed with the Pearson 
c2 test. Repeated measurements of patients with 
both, 2- and 6-month follow-up, were analyzed 
with the non-parametric paired Wilcoxon signed-
UDQNWHVW6WDWLVWLFDOVLJQLğFDQFHZDVDVVXPHGIRU
p-values < 0.05.
Results
Study population
Altogether 33 lesions were treated. Six-month 
follow-up with QCA and OCT analyses was avail-
able in 24 patients. Sixteen patients returning to 
the clinic for staged PCI within 2 months after 
index PCI received OCT imaging of the study 
vessel. Among them, 7 patients also returned for 
6-month invasive follow-up (Fig. 1). Tables 1 and 2 
show clinical and procedural characteristics. Pre-
dilation was conducted with a mean of 1.69 ± 2.2 in 
the 2-month follow-up group and 0.96 ± 1.3 times 
Table 1. Baseline clinical characteristics of the study population, patient-based analysis.
Characteristics Patients with 2-month 
follow-up 
Patients with 6-month 
follow-up
P All
N 16# 24# 32
Age 69.1 ± 7.2 68.9 ± 7.8 0.953 69.3 ± 7.7
Male gender 11 (68.8%) 15 (62.5%) 0.685 22 (68.8%)
Coronary risk factors:
Hypertension 16 (100%) 24 (100%) 0.999 32 (100%)
Diabetes mellitus 10 (62.5%) 7 (29.2%) 0.037 14 (43.8%)
Hyperlipidemia 11 (68.8%) 19 (79.2%) 0.320 24 (75.0%)
Smoker/Ex-smoker 3 (18.8%) 9 (37.5%) 0.722 9 (28.1%)
Glomerular filtration rate [mL/min] 70.7 ± 25.2 64.3 ± 22.8 0.418 69.2 ± 22.4
Low-density lipoprotein [mmol/L] 2.3 ± 0.9 3.0 ± 1.6 0.148 2.8 ± 1.5
Previous myocardial infarction 6 (37.5%) 4 (16.7%) 0.136 8 (25.0%)
Previous coronary artery bypass graft 0 0 0.999 0
Data are expressed as mean ± standard deviation or number (%) of subjects; #7 patients with 8-week and 6-month follow-up belong to both 
groups
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in the 6-month follow-up group (NS). The relation 
RILQĠDWHGVWHQWGLDPHWHUV6'WRUHIHUHQFHYHV-
sel diameters (RVD: given as mean values of two 
diameter measurements per proximal and distal 
reference site) yields an overstretch ratio (SD/ 
/RVDOCT) of 106.9 ± 17.8% (Table 2).
Comparison of invasive follow-up  
at 2 and 6 months
6WUXWOHYHODQDO\VLVVKRZHGVLJQLğFDQWO\PRUH
ISA at 2 months compared to 6 month-follow-up 
(11.4 ± 11.8% vs. 2.2 ± 5.0%; p = 0.001) (Table 3, 
Fig. 2), which was depicted with various OCT 
parameters (number of ISA regions, ISA volumes, 
ISA depth and ISA surface areas) (Table 3) and 
went along with significantly more unco-
vered struts compared to 6-month follow-up 
(14.5 ± 14.8% vs. 2.0 ± 5.3%, p = 0.001) 
(Table 3). We noted positive vessel remodeling 
with larger remodeling volumes after 2 months 
compared to 6 months (0.26 ± 0.35 mm3/cm 
vs. 0.11 ± 0.14 mm3/cm, p = 0.071). At 6 months 
the suspected positive vessel remodeling with 
severe ISA was largely reversible (Table 3, Fig. 2). 
1RWDOOSDUDPHWHUVUHDFKHGVWDWLVWLFDOVLJQLğFDQFH
in this small sample size. OCT analysis revealed 
well expanded stents (inflated SDnominal: 2.86 ± 
± 0.23 vs. median measured SDOCT: 2.89 ± 0.41). 
Measured SD and stent areas (SA) in relation to 
WKHLULQĠDWHGQRPLQDOYDOXHV>6'median – SDnominal]/ 
/SDnominal; [SAmedian – SAnominal]/SAnominal) indicated slight 
overexpansion of most stents (0.8 ± 10.9%; and 
3.3 ± 20.6%, respectively). We found no relation-
ship between stent sizes and ISA.
Serial analysis of the same stent  
at 2- and 6-month follow-up
We found significantly greater remodeling 
volumes, larger ISA depths, more ISA regions 
and more uncovered struts at the early 2-month 
Table 2. Procedural and lesion characteristics, lesion-based analysis.
Characteristics Patients with 2-month 
follow-up 
Patients with 6-month 
follow-up
P All
N 16# 25*# 33*#
Follow-up interval [days] 61.9 ± 11.3 189.2 ± 20.8 < 0.001
Baseline stenosis [%] 82.8 ± 10.9 72.5 ± 15.3 0.024 74.1 ± 14.4
Target vessel: 0.932
Right coronary artery 4 (25.0%) 7 (28.0%) 9 (27.3%)
Left circumflex 4 (25.0%) 7 (28.0%) 8 (24.2%)
Left anterior descending 8 (50.0%) 11 (44.0%) 16 (48.5%)
Lesion type (ACC/AHA): 0.961
Type A 0 0 0
Type B
Type C
10 (62.5%)
6 (37.5%) 
17 (68.0%)
8 (32.0%)
22 (66.7%)
11 (33.3%)
Procedural parameters:
2.5 mm stent diameter
3.0 mm stent diameter
5 (31.3%)
11 (68.8%)
7 (28.0%)
18 (72.0%)
0.832
10 (30.3%)
23 (69.7%)
Stent length [mm] 20.5 ± 4.6 19.7 ± 4.5 0.575 19.9 ± 4.5
Overstretch ratio [%] 103.2 ± 10.4 109.3 ± 21.2 0.304 106.9 ± 17.8
Direct stenting 5 (31.3%) 14 (56.0%) 0.379 15 (45.5%)
Ostial lesion 0 1 (4.0%) 0.418 1 (3.0%)
Additional stenting 2 (12.5%) 5 (20.0%) 1.0 5 (15.2%)
Chronic total occlusion 2 (12.5%) 3 (12.0%) 0.962 4 (12.1)
Bifurcation lesion 2 (12.5%) 4 (16.0%) 0.757 5 (15.2)
Side branch dilation 0 1 (4.0%) 0.418 1 (3.0%)
Time of fluoroscopy [min] 11.9 ± 7.2 10.2 ± 9.5 0.573 10.8 ± 9.4
Procedural success 16 (100%) 25 (100%) 0.999 33 (100%)
*1 patient had only an angiographic follow-up without optical coherence tomography imaging; #7 lesions (7 patients) were included in both 
groups due to sequential follow-up and 1 patient was included with 2 study lesions
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follow-up and reversible effects after 6 months 
(Table 4) corresponding to the shown interindi-
vidual analysis above (Figs. 3, 4).
OCT “carpet view”
Of each investigated stented vessel segment, 
a 3D spread out chart was created. The 3D illus-
trates (1) stent circumference (X-axis and blue line), 
(2) analyzed stent or vessel length and, (3) degree 
of stent incorporation in the vessel wall (neointi-
mal thickness of stent struts, negative values), or 
distance of struts with ISA from luminal border 
(positive values) (Figs. 3, 4). Stent struts are dis-
played as colored dots depending on their quality 
of coverage and apposition.
Discussion
Data regarding an a priori strategy of BMS 
+ PCB in de novo coronary artery stenoses are still 
OLPLWHG>ļ@3UHYLRXVO\WKHğQDO\HDUUHVXOWV
of the PERfECT trial, a randomized study of BMS/ 
/PCB vs. BMS in de novo stenoses showed supe-
riority for an adjunctive delivery of paclitaxel by 
a coated balloon for clinical endpoints [10]. O the 
contrary, another recently published randomized 
study found an increased stent thrombosis rate 
for the concept of BMS + PCB compared to the 
SDFOLWD[HOHOXWLQJVWHQWV>@7KLVLVWKHğUVWVWXG\
investigating the course of vessel healing after 
a BMS + PCB approach using QCA and OCT.
Table 3. Comparison of implanted stents at 8-week and 6-month invasive follow-up, lesion-based 
analysis.
Characteristics 2-months follow-up  
(n = 16)#
6-months  follow-up 
(n = 25)*#
P
QCA parameters
RLD [mm] 2.61 ± 0.3 2.65 ± 0.31 0.714
MLD at baseline [mm] 0.43 ± 0.28 0.72 ± 0.43 0.027
MLD at fallow-up [mm] 2.23 ± 0.45 2.06 ±  0.41 0.219
Post-procedure MLD [mm] 2.31 ± 0.4 2.29 ± 0.34 0.794
Baseline stenosis [%] 82.8 ± 10.9 72.5 ± 15.3 0.024
Post-procedure stenosis [%] 10.8 ± 10.2 12.7 ± 9.6 0.536
Stenosis at follow-up [%] 14.4 ± 12.5 21.8 ± 13.0 0.080
Late lumen loss at follow-up 0.09 ± 0.14 0.23 ± 0.21 0.028
Net luminal gain at follow-up 1.82 ± 0.5 1.38 ± 0.6 0.024
OCT — proliferation analysis  
Analyzed stent length [%] 98.4 ± 11.1 71.7 ± 24.8 < 0.001
Relative proliferation volume [mm3/cm stent] 5.1 ± 7.8 13.6 ± 7.4 0.001
Peak relative proliferation area [%] 26.1 ± 13.6 40.0 ± 15.0 0.009
Median relative proliferation area [%] 10.2 ± 8.0 23.1 ± 10.5 < 0.001
OCT — ISA analysis
Positive remodeling volume [mm3] 4.9 ± 5.9 2.0  ± 2.6 0.042
Positive remodeling volume [mm3/cm stent] 0.26 ± 0.35 0.11 ± 0.14 0.071
Number of ISA regions 2.1 ± 2.2 0.3 ± 0.6 < 0.001
Maximal ISA depth [μm] 215 ± 690 10 ± 25 0.151
Maximal ISA volume [mm3] 3.62 ± 7.7 0.41 ± 1.6 0.054
Total ISA volume [mm3] 5.62 ± 12.6 0.46 ± 1.8 0.054
Relative ISA volume [%] 3.67 ± 8.0 0.37 ± 1.5 0.056
Total ISA surface [mm²] 5.27 ± 6.7 1.36 ± 4.4 0.032
Relative ISA surface [%] 2.79 ± 3.6 0.83 ± 2.8 0.063
Struts with ISA [%] 11.4 ± 11.8 1.8 ± 4.8 0.001
Uncovered struts [%] 14.5 ± 14.8 2.0 ± 5.3 0.001
*1 patient had only an angiographic follow-up without OCT imaging; #7 lesions (7 patients) were included in both groups due to sequential 
follow-up and 1 patient was included with 2 study lesions; ISA — incomplete stent apposition; MLD — minimal lumen diameter; OCT — optical 
coherence tomography; QCA — quantitative coronary angiography; RLD — reference lumen diameter
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Figure 2. Remodeling volume, percent struts with incomplete stent apposition (ISA) and percent uncovered struts 
(means and standard errors of the mean) comparing study stents after 2 and 6 months. A. Entire study population; 
B. Serial comparison in 7 patients; *p < 0.05; **p = 0.001.
Table 4. Serial analysis of the same study stent at 2- and 6-month follow-up, lesion-based analysis 
[mean ± SD (median)].
2-month follow-up  
(n = 7)
6-month follow-up  
(n = 7)
P
Follow-up interval [days] 67.7 ± 8.0 (65.0) 204.9 ± 22.4 (209.0) 0.018
QCA parameters
RLD [mm] 2.6 ± 0.37 (2.6)
MLD at baseline [mm] 0.36 ± 0.3 (0.3)
MLD at follow-up [mm] 2.26 ± 0.48 (2.32) 2.15 ± 0.47 (2.2) 0.018
Baseline stenosis [%] 85.6 ± 11.5 (84.0)
Stenosis at follow-up [%] 12.3 ± 13.6 (8.0) 16.6 ± 14.2 (12.0) 0.018
Late lumen loss at follow-up 0.049 ± 0.17 (0.08) 0.163 ± 0.17 (0.17) 0.018
Net luminal gain at follow-up 1.96 ± 0.51 (2.0) 1.79 ± 0.62 (1.67) 0.063
OCT — proliferation analysis  
Analyzed stent length [%] 95.8 ± 9.3 (95.2) 91.8 ± 11.3 (87.0) 0.128
Relative proliferation volume [mm3/cm stent] 2.2 ± 8.0 (2.4) 7.5 ± 6.5 (8.4) 0.018
Peak relative proliferation area [%] 21.6 ± 12.2 (23.1) 29.9 ± 11.5 (34.0) 0.028
Median relative proliferation area [%] 6.3 ± 6.6 (5.8) 15.6 ± 10.7 (19.1) 0.018
OCT — ISA analysis
Positive remodeling volume [mm3] 6.84 ± 7.6 (5.85) 2.98 ± 3.6 (1.0) 0.046
Positive remodeling volume [mm3/cm stent] 0.35 ± 0.45 0.16 ± 0.18 0.116
Number of ISA regions 2.86 ± 2.3 (2.0) 0.71 ± 1.0 (0) 0.026
Maximal ISA depth [μm] 452 ± 104 (49) 28 ± 40 (0) 0.028
Maximal ISA volume [mm3] 4.68 ± 10.1 (0.38) 1.39 ± 2.9 (0) 0.128
Total ISA volume [mm3] 8.37 ± 18.3 (0.38) 1.54 ± 3.2 (0) 0.128
Total ISA surface [mm2] 5.46 ± 5.8 (1.64) 4.52 ± 7.6 (0) 0.237
Relative ISA surface [%] 5.2 ± 11.7 (1.17) 2.75 ± 5.0 (0) 0.128
Struts with ISA [%] 16.9 ± 13.7 (16.1) 5.7 ± 7.8 (0.6) 0.018
Uncovered struts [%] 21.4 ± 17.9 (20.4) 6.4 ± 8.8 (1.1) 0.018
ISA — incomplete stent apposition; MLD — minimal lumen diameter; OCT — optical coherence tomography; QCA — quantitative coronary 
angiography; RLD — reference lumen diameter
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Figure 3. Serial optical coherence tomography (OCT) assessment of stent strut incorporation and neointimal growth 
showing resolution of an incomplete stent apposition area (ISA) between the 2-month (left panels) and 6-month 
results (right panels). Top: Cross-sectional two-dimensional (2D)-OCT images; Middle: longitudinal 2D-OCT views; 
Bottom: 3D-OCT spread-outs (“carpet-views”) of the stent segment, showing the position and coverage thickness of 
the struts, uncovered struts in red, apposed and covered struts in yellow, embedded struts in green. X-axis — stent 
circumference; Y-axis — analyzed stent length. Grey scale: (–) values — neointimal thickness, (+) values — mal-ap-
position distance from luminal border. Displayed cross-section at 2-and 6-month follow-up is indicated as blue circle.
Strut coverage and neointimal proliferation
We found a high percentage of uncovered 
struts (14.5 ± 14.8%) 2 months after a combina-
tion therapy of BMS + PCB. Histological studies 
showed an increased risk of stent thrombosis if 
≥ 30% of struts are uncovered [14]. With respect 
to the standard deviation of our results, dura-
tion of dual antiplatelet therapy below 6 should 
be avoided. Stent coverage after a BMS + PCB 
approach is similar to those of paclitaxel- and 
sirolimus-eluting stents after 6 months (~5–8% 
uncovered struts) [6, 9, 15, 16]. However, newer 
generation everolimus- and zotarolimus-eluting 
stents seem to have a better (0.1 ± 0.4% after 
6 months) and faster stent endothelialization 
(4.7 ± 5.7–6.2 ± 6.9% after 3 months) [15, 17].
Incomplete stent apposition  
and positive vessel remodeling
At early 2-month follow-up we found severe 
,6$ZKLFKZHDVFULEHWRVLJQLğFDQWYHVVHOZDOOH[-
pansion. Since we did not perform OCT at baseline, 
positive vessel remodeling cannot be completely 
proven. However, chosen stent diameters were 
appropriate according to RVDs and stents were 
well expanded. There was no clustering of areas 
with ISA, neither at the stent edges nor elsewhere. 
ISA were distributed over the entire stent length 
involving only small sectors and not more than 
a quadrant per cross-section.
Histological studies showed that paclitaxel 
leads to vessel wall dilation due to a decrease in 
media wall thickness, focal wall hemorrhage and 
cell necrosis [18, 19]. Vascular enlargement after 
a “paclitaxel-coated balloon only” approach for de 
novo coronary stenosis has been demonstrated 
[20, 21]. Thus, our results give the pathophysiolog-
ical clue (focal positive vessel remodeling) for the 
increased stent thrombosis rates after BMS/PCB 
as previously published [13]. Furthermore, the 
reversibility of the observed positive remodeling 
SKHQRPHQRQLVXQGHUOLQHGE\WKHğQGLQJWKDWVWHQW
WKURPERVLVRFFXUVHDUO\ZLWKLQWKHğUVWGD\V
after a BMS/PCB procedure. It has been shown that 
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Figure 4. Three-dimensional “carpet views” — patients comparing 2-month (left column) vs. 6-month (right column) 
follow-up. Blue line indicates length of the circumference (perimeter) of the stent. Uncovered struts are displayed in 
red, apposed and covered struts in yellow, embedded struts in green. X-axis — stent circumference; Y-axis — ana-
lyzed stent length. Grey scale: (–) values — neointimal thickness, (+) values — mal-apposition distance from luminal 
border.
there is a delayed arterial healing for ISA depths 
≥ŝP,6$GHSWKDWPRQWKIROORZXSLQRXU
VWXG\řŝP>@,QWHUHVWLQJO\GHOLYHU\
of paclitaxel via a polymer-stent-matrix seems to 
induce different or rather alleviated focal vessel 
effects [10]. PCB induce a much higher paclitaxel 
WLVVXHFRQFHQWUDWLRQaŝJJWLVVXHFRPSDUHG
WRSDFOLWD[HOHOXWLQJVWHQWVaŝJJWLVVXH>
24], and dose-dependent positive vessel remod-
eling with reversible effects at long-term follow-up 
have been observed [25–28]. Paclitaxel induces 
DKLJKHUDFXWHLQĠDPPDWRU\YHVVHOUHDFWLRQFRP-
pared to mTOR inhibitors. Histological analysis 
of a BMS + PCB combination in a swine model 
also revealed delayed stent endothelialization and 
LQFUHDVHGğEULQGHSRVLWLRQ>@
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OCT “carpet view”
)RUWKHğUVWWLPHDFRPSOH[DOJRULWKPEDVHGRQ
manual input of stent struts and vessel dimensions 
which enables a real 3D picture of stented vessel 
segments as spread out was implemented (“car-
pet view”, Figs. 3, 4). This novel comprehensive 
illustration of OCT-derived parameters enables 
recognition of strut coverage including neointimal 
thickness, distribution of ISA clusters and assess-
ment of lumen and stent perimeters at a glance.
Clinical implications
We see no added clinical value for a primary 
strategy using BMS + PCB compared to mod-
ern DES given the large amounts of ISA after 
2 months, lack of better stent coverage and the 
lower anti-proliferative effects [7–9, 31]. In case 
of bailout situations during a planned “PCB only” 
intervention with the need for subsequent stent 
implantation, short duration of dual antiplatelet 
therapy might be harmful.
Limitations of the study
Our patient cohort is relatively small and the 
study was not aligned for clinical endpoints. Cal-
culated remodeling volumes are only surrogate 
SDUDPHWHUVEHWWHUGHğQLWLRQYHVVHOYROXPHIROORZ
-up – vessel volume post-PCI) since OCT was not 
performed at baseline. Due to clustered data, the 
statistical analysis should be considered an approxi-
mation. We decided to simplify the analysis and its 
methodological description, since only secondary 
endpoints of the study were affected by this potential 
limitation. A true serial study was only performed in 
7 patients, which is methodologically an insolvable 
problem, because the 2-month/6-month groups can 
be statistically analyzed neither as independent nor 
as paired samples.
Conclusions
Bare metal stenting in combination with si-
multaneous application of paclitaxel by a balloon 
shows transient severe ISA, most likely due to focal 
SRVLWLYHYHVVHOUHPRGHOLQJ2XUğQGLQJVXQGHUOLQH
WKHVSHFLğFYHVVHOHIIHFWVRISDFOLWD[HOZKLFKVHHP
to be, at least temporarily, unfavorable in combina-
tion with a stent cage. The novel 3D “carpet-view” 
HQDEOHVIRUWKHğUVWWLPHWKHUHFRJQLWLRQRIVWUXW
apposition and coverage, neointima proliferation, 
distribution of clusters and assessment of lumen 
and stent perimeters at a glance.
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